These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18362292)

  • 1. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.
    Plöckinger U; Reuter T
    Eur J Endocrinol; 2008 Apr; 158(4):467-71. PubMed ID: 18362292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
    Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
    Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities.
    Olarescu NC; Ueland T; Godang K; Lindberg-Larsen R; Jørgensen JO; Bollerslev J
    Eur J Endocrinol; 2014 Jan; 170(1):39-48. PubMed ID: 24092547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
    Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
    Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of medical therapies for acromegaly on glucose metabolism.
    Urbani C; Sardella C; Calevro A; Rossi G; Scattina I; Lombardi M; Lupi I; Manetti L; Martino E; Bogazzi F
    Eur J Endocrinol; 2013 Jul; 169(1):99-108. PubMed ID: 23660641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.
    Ciresi A; Amato MC; Pizzolanti G; Giordano Galluzzo C
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2907-15. PubMed ID: 22679062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
    Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
    Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment.
    Olarescu NC; Heck A; Godang K; Ueland T; Bollerslev J
    Neuroendocrinology; 2016; 103(3-4):197-206. PubMed ID: 25592241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
    Niculescu D; Purice M; Coculescu M
    Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
    Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.